Clinica Valle Giulia, GeneraLife IVF, Via G. de Notaris 2B, 00197, Rome, Italy.
Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
J Assist Reprod Genet. 2023 Jan;40(1):169-177. doi: 10.1007/s10815-022-02684-w. Epub 2022 Dec 31.
An impact of different gonadotrophins selection for ovarian stimulation (OS) on oocyte competence has yet to be defined. In this study, we asked whether an association exists between OS protocol and euploid blastocyst rate (EBR) per metaphase-II (MII) oocytes.
Cycles of first preimplantation genetic testing for aneuploidies conducted by women ≥ 35 years old with their own metaphase-II oocytes inseminated in the absence of severe male factor (years 2014-2018) were clustered based on whether recombinant FSH (rec-FSH) or human menopausal gonadotrophin (HMG) was used for OS, then matched for the number of fresh inseminated eggs. Four groups were outlined: rec-FSH (N = 57), rec-FSH plus rec-LH (N = 55), rec-FSH plus HMG (N = 112), and HMG-only (N = 127). Intracytoplasmic sperm injection, continuous blastocyst culture, comprehensive chromosome testing to assess full-chromosome non-mosaic aneuploidies and vitrified-warmed euploid single embryo transfers (SETs) were performed. The primary outcome was the EBR per cohort of MII oocytes. The secondary outcome was the live birth rate (LBR) per first SETs.
Rec-FSH protocol was shorter and characterized by lower total gonadotrophin (Gn) dose. The linear regression model adjusted for maternal age showed no association between the Gn adopted for OS and EBR per cohort of MII oocytes. Similarly, no association was reported with the LBR per first SETs, even when adjusting for blastocyst quality and day of full blastulation.
In view of enhanced personalization in OS, clinicians shall focus on different endpoints or quantitative effects related to Gn action towards follicle recruitment, development, and atresia. Here, LH and/or hCG was administered exclusively to women with expected sub/poor response; therefore, we cannot exclude that specific Gn formulations may impact patient prognosis in other populations.
不同促性腺激素选择对卵巢刺激(OS)的影响对卵母细胞的能力尚未确定。在这项研究中,我们询问 OS 方案与中 MII 期卵母细胞的整倍体囊胚率(EBR)之间是否存在关联。
对 2014-2018 年间年龄≥35 岁的女性进行的首例植入前遗传学非整倍体检测(PGT-A)周期中,使用自身的 MII 期卵母细胞进行未受精,排除严重的男性因素(年)。根据是否使用重组促卵泡激素(rec-FSH)或人绝经期促性腺激素(HMG)进行 OS,将这些周期进行聚类,然后按新鲜授精卵的数量进行匹配。概述了四个组:rec-FSH(N=57)、rec-FSH+rec-LH(N=55)、rec-FSH+HMG(N=112)和 HMG 仅(N=127)。进行了胞浆内精子注射、连续囊胚培养、综合染色体测试以评估全染色体非整倍体和玻璃化冷冻解冻的整倍体单胚胎移植(SET)。主要结果是每批 MII 卵母细胞的 EBR。次要结果是每例首次 SET 的活产率(LBR)。
rec-FSH 方案更短,总促性腺激素(Gn)剂量更低。调整母体年龄的线性回归模型显示,OS 中使用的 Gn 与每批 MII 卵母细胞的 EBR 之间没有关联。同样,即使调整囊胚质量和完全囊胚化日,首次 SET 的 LBR 也没有报道。
鉴于 OS 中的个性化增强,临床医生应关注与 Gn 对卵泡募集、发育和闭锁的作用相关的不同终点或定量效应。在这里,LH 和/或 hCG 仅在预期低/反应不佳的患者中使用;因此,我们不能排除特定的 Gn 制剂可能会对其他人群的患者预后产生影响。